Back to search

Aristotle University Of Thessaloniki (AUTH)

Ανάπτυξη και αξιολόγηση εφαρμογών βιοπληροφορικής με κλινική χρησιμότητα στη γενετική του καρκίνου

Abstract

dc:description

Precision Medicine is an emerging approach to medicine that studies the genetic profile of each patient, aiming in providing personalized treatment and preventing disease. Cancer is a disease of the genome, so precision medicine has a special application in oncology. More specifically, one of the main goals of precision medicine in oncology is to identify the distinct genetic features of each patient's tumor and, consequently, to provide specific treatment that targets them. Additionally, another aspect of precision medicine in oncology is disease prevention, through the study of hereditary cancer, which allows the timely identification of individuals who are at increased risk of developing cancer and, ultimately, their proper clinical management.In recent years, DNA sequencing technology has rapidly evolved thanks to technological improvements and new automation methods. The introduction of Next Generation Sequencing resulted in the production of a large volume of genetic data, which allows the understanding of the biological machineries that govern human disease. These developments have paved the way to precision medicine; they have also introduced new challenges regarding the analysis, the recording, and the distribution of this huge amount of data.Bioinformatics is a science that has decidedly contributed to addressing these challenges. By allowing the analysis of large-scale raw data that is impossible to analyze manually, the integration of heterogeneous biological data, and the use of advanced computational and statistical methods to understand them, bioinformatics provides the tools for detecting biomarkers and candidate drugs. Moreover, many biological databases have been created for storing this huge amount of data, enabling easy data management, and sharing with the scientific community.The aim of the present thesis is the study of bioinformatics applications with clinical utility in cancer genetics and precision medicine. In this context, CanVaS (Cancer Variation reSource), the first database on hereditary cancer for the Greek population, was developed, recording the genetic heterogeneity of Greek cancer patients along with their phenotypic and clinical characteristics. Moreover, VarTrace, a pipeline for the analysis of genetic data generated from Next Generation Sequencing of tumor DNA is presented. Finally, a commercial software for the annotation of germline variants identified through Next Generation Sequencing was evaluated.The advent of Next Generation Sequencing technology has introduced the need to record population-specific genetic data. National genetic variation registries vastly increase the level of detail for the relevant population, while directly affecting patient management. CanVaS comprises a collection of data from the genetic analyses of 7,363 Greek patients that have been diagnosed with various types of cancer and/or cancer syndromes and their healthy relatives. All these individuals have been tested in the Molecular Diagnostics Laboratory of NCSR "Demokritos" for germline variants in 1 to 97 genes that have been associated with predisposition to cancer. The CanVaS data collection consists of approximately 24,000 functionally annotated variants. For each variant, the allele frequency for the Greek population, its evaluation, interpretation, and clinical impact according to the American College of Clinical Geneticists (ACMG) guidelines are recorded. Most importantly, the genetic dataset is accompanied by the phenotypic and clinical traits of the carriers. Moreover, information on the geographical distribution of the variants throughout the country is provided, allowing the study of Greek isolates. CanVaS is developed using the Leiden Open Variation Database (LOVD) open-source software, allowing easy connection to central data sources. This way, it serves as a part of the solution to the divided availability of genetic data in many different databases. CanVaS is available at: http://ithaka.rrp.demokritos.gr/CanVaS. The VarTrace pipeline was developed to accurately detect somatic variants in tumor DNA. Next Generation Sequencing of somatic DNA is widely used for biomarker detection that can be targeted for personalized treatment. A prominent example is the assessment of homologous recombination deficiency in tumors, through the detection of pathogenic variants in BRCA1 and BRCA2. Patients with homologous recombination deficient tumors can benefit from the administration of poly ADP ribose polymerase (PARP)-inhibitors. However, tumor DNA sequencing bears many challenges, as the tumor genome is vastly heterogeneous and existing tissue preservation methods alter its genetic material. As a result, tumor DNA sequencing often leads to the detection of an increased number of false-positive variants. VarTrace addresses these limitations using multiple variant calling algorithms and fine-tuned customization of its parameters. To demonstrate its efficacy and utility, we applied VarTrace to data from the sequencing of BRCA1 and BRCA2 genes in 75 patients with ovarian epithelial carcinoma and compared the results with two commercially available pipelines. VarTrace is an automated, fully configurable, and parallel pipeline, written in R and Perl and is available at: https://gitlab.com/dkalfakakou/TumorPipeline.Finally, we evaluated the variant annotation performed by a user-friendly and commercially available software, Illumina® VariantStudio v3.0 (VS), on a clinical setting. VS uses a specific set of transcripts for the annotation process. For the sake of comparison, we employed Ensembl VEP, an open source command line tool, which provides flexibility in transcript selection. Data from the germline DNA sequencing of 857 cancer patients that were analyzed using Next Generation Sequencing were used for the evaluation. The comparison between the two transcript sets showed a discordance rate of 82.82%. Moreover, using the default VS transcript set, 11.45% of the identified loss-of-function variants were characterized incorrectly. In the case of a clinical application of genetic testing, these results could directly and negatively impact patient management. Our results highlight the importance of careful software and transcript selection and the need for reliable data analysis, in order to reduce the error rate of genetic testing and, consequently, improve patient care.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kalfakakou, Despoina
  • Καλφακάκου, Δέσποινα

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/50009

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kalfakakou, Despoina; Καλφακάκου, Δέσποινα. Ανάπτυξη και αξιολόγηση εφαρμογών βιοπληροφορικής με κλινική χρησιμότητα στη γενετική του καρκίνου. Aristotle University Of Thessaloniki (AUTH), 2021. http://hdl.handle.net/10442/hedi/50009